Update on CoC Quality Measures, Standards, Lymph Node Counts for Lung Cancer

Linda Martin, MD, MPH

Associate Professor with Tenure, Thoracic Surgery Interim Chief, Division of Thoracic Surgery University of Virginia School of Medicine





Financial Disclosures

Commercial Interest	Relationship(s)
Astra Zeneca	Advisory Board for Adaura Trial dissemination
On Target Laboratories	Steering Committee for ELUCIDATE trial



"People never improve unless they look to some standard or example higher or better than themselves." Tyron Edwards, American theologian 1809-1894





A QUALITY PROGRAM of the AMERICAN COLLEGE OF SURGEONS



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality: Highest Standards, Better Outcomes



Commission on Cancer in Today's Health Care Environment

The multidisciplinary Commission on Cancer:

- Establishes standards to ensure high-quality, multidisciplinary and comprehensive cancer care.
- Conducts surveys at cancer programs to assess compliance with those standards.
- Collects standardized high-quality data from CoC-accredited organizations.
- Uses data to measure cancer care quality and to monitor treatment patterns and outcomes.
- Requires cancer prevention and screening at programs.
- Monitors clinical surveillance activities.
- Develops effective educational programs to achieve its goals.

CoC Quality of Care Measures - Lung Cancer OLD GUIDELINES

N S Not Applicable		At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC	Fall 2014
QI	Standard 4.5 85%	Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.	Fall 2014
QI	Standard 4.5 85%	Surgery is not the first course of treatment for cN2, M0 lung cases	Spring 2015
	QI	Applicable QI Standard 4.5 85% QI Standard 4.5	Applicable pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC Standard 4.5 Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC. QI Standard 4.5 Surgery is not the first course of treatment for cN2, M0 lung cases

S = surveillance measure; (for informative purposes) QI = Quality Improvement; (for internal monitoring)

A = Accountability (could be used for public reporting)

CoC Quality of Care *Measures* - Lung Cancer *OLD GUIDELINES*

Non-Small Cell Lung				
10RLN	8	-Not Applicable	At least 10 regional lymph nodes are removed and pathologically examined for AJOC stage IA, IB, IIA, and IIB resected NOCLO	Fall 2014
LCT	QI Standard 4.5 85%		.5 Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.	Fall 2014
LNoSurg	QI	Standard 4.5 85%	Surgery is not the first course of treatment for cN2, M0 lung cases	Spring 2015

S = surveillance measure; (for informative purposes) QI = Quality Improvement; (for internal monitoring)

A = Accountability (could be used for public reporting)

NEW **MEASURES** COMING IN NEXT 1-2 YEARS



Cancer Surgery **Standards** Program (CSSP)


• The ACS launched the CSSP in June 2020, recognizing growing evidence that adherence to specific operative techniques leads to:

Longer survival

Better surgical outcomes

Improved quality of life







Shift from standards based in facilities/equipment to outcomes-based standards





Cancer Surgery Standards Program (CSSP)

• Mission: To improve the quality of care for persons with cancer


Goals:


- Set evidence-based standards for the technical conduct of oncologic surgery
- Educate surgeons on the key technical aspects of oncologic procedures
- Create tools which support implementation and adherence to the standards
 - Synoptic operative report templates





Cancer Surgery Standards Program (CSSP)










The CoC Operative Standards (2020)



Standard	Disease Site	Procedure	Documentation
5.3	Breast	Sentinel node biopsy	Operative report
5.4	Breast	Axillary dissection	Operative report
5.5	Melanoma	Wide local excision	Operative report
5.6	Colon	Colectomy (any)	Operative report
5.7	Rectum	Mid/low resection (TME)	Pathology report (CAP)
5.8	Lung	Lung resection (any)	Pathology report (CAP)





Multidisciplinary Panel



Michael Archer, DO
SUNY Upstate
Thoracic Surgery



Kimberly Absher, MD
UK Markey Cancer Center
Pathology



Lexy Adams, MD MPH Brooke Army Medical Center General Surgery Resident



Jennie Jones MSHI-HA, CHDA, CTR

Moffitt Cancer Center

Cancer Registry Director



Timothy Mullett, MD FACS

UK Markey Cancer Center

Thoracic Surgery

Chair, Commission on Cancer



Raymond Osarogiagbon, MD

Baptist Cancer Center

Medical Oncology





Standard 5.8: Lung Resection Rationale



Pulmonary Nodal Staging as an Operative Standard: Rationale


- Staging is dependent on status of N1 and N2 nodal stations
- Mediastinal lymph node assessment is recommended
- Audits of surgeon operative notes and pathology reports show poor concordance regarding procedure performed and extent of lymph node sampling





Mediastinal Lymph Node Assessment

Overall Survival by Arm - Eligible patients




ACOSOG Z0030:

Equivalent survival for

Systematic Mediastinal lymph node sampling (MLNS)

VS

Mediastinal lymph node dissection (MLND)








Examining Mediastinal Lymph Nodes

Improves Survival








Examining Mediastinal Lymph Nodes Improves Survival

Following NCCN guidelines improves survival

NCCN Guidelines:

- 1. Anatomic resection
- 2. Negative margins
- 3. Examination of hilar/intrapulmonary LNs
- Examination of ≥3 mediastinal LNs







Pulmonary Resection Critical Elements: Lymph node staging

- Mediastinal staging prior to treatment (radiographic or invasive)
- Invasive mediastinal staging for central tumors, clinical N1 disease and tumors
 >3cm
- Confirmation of imaging findings at thoracic exploration
- Mediastinal staging at the time of lung resection

Any curative intent lung resection, including:

Non-small cell lung cancer
Small cell lung cancer
Carcinoid tumor





Standard 5.8: Pulmonary Nodal Staging

1 hilar lymph node

L + RULE

3

3 mediastinal lymph nodes (3 distinct stations)





Standard 5.8: Lung Resection Technique



Pulmonary Resection: Lymph Node Stations

LEFT
9L
8L
7
6
5
(4L & 2L
if accessible)





9R 8R 7 10R 4R 2R


Mediastinal stations:
Single digit (2-9)
Hilar stations:
Double digit (10+)




Lymph Node Stations
















Pulmonary resection: Technique (right)

Right sided approach to stations 8 (para-esophageal) & 9 (inferior pulmonary ligament)














Pulmonary resection: Technique (right)

Right sided approach to station 7 (subcarinal)














Pulmonary resection: Technique (right)

Right sided approach to stations 2R (upper paratracheal) and 4R (lower paratracheal)












Pulmonary resection: Technique (left)

Left sided approach to stations 5 (sub-aortic) and 6 (para-aortic)







Standard 5.8: Pulmonary Nodal Staging

1 hilar lymph node

L + RULE

3

3 mediastinal lymph nodes (3 distinct stations)





Standard 5.8: Lung Resection Documentation, Implementation Timeline & Compliance



CoC Compliance Measures: Standard 5.8

- 1) The hilum and mediastinum should be **thoroughly staged at the time of lung resection**, even in patients undergoing non-anatomic parenchyma sparing resection (i.e. a wedge resection)
- 2) The surgical pathology report must contain lymph nodes from at least one hilar station and at least three distinct mediastinal stations
- 3) The nodal stations examined by the pathologist must be documented in curative pulmonary resection pathology reports in synoptic format





Example of a CAP Lung Resection Synoptic Report

CAP Approved

Thorax • Lung • Resection • 4.1.0.1

Surgical Pathology Cancer Case Summary
Protocol posting date: February 2020
LUNG: Resection
Select a single response unless otherwise indicated.
Synchronous Tumors (required if morphologically distinct unrelated multiple primary tumors are present) Present*
Procedure (select all that apply) Wedge resection Segmentectomy Lobectomy Completion lobectomy Sleeve lobectomy Bilobectomy Pneumonectomy Major airway resection (specify): Other (specify): Not specified
(and other sections) Lymph Node Examination (required only if lymph nodes present in the specimen)
Number of Lymph Nodes Involved: Number cannot be determined (explain): Specify nodal station(s) involved (applicable only if node(s) involved): Number of Lymph Nodes Examined:
Number cannot be determined (explain): Specify nodal station(s) examined:
+ Extranodal Extension (Note J) + Not identified + Present + Cannot be determined
Treatment Effect (Note I) No known presurgical therapy Greater than 10% residual viable tumor Less than or equal to 10% residual viable tumor Cannot be determined

Number of Lymph Nodes Involved: Number cannot be determined (explain): Specify nodal station(s) involved (applicable only if node(s) involved):
Number of Lymph Nodes Examined: Number cannot be determined (explain): Specify nodal station(s) examined:





How will compliance be assessed?

 A site visit reviewer will review the standardized synoptic pathology reports for curative intent pulmonary resections

By 2022, sites will be expected to have 70% compliance





Timeline to Achieve Compliance: Standard 5.8







Compliance levels for 5.7 & 5.8

Visit Year	Standard	Materials Assessed	Requirement
2022	5.7	7 rectal pathology reports from 2021	70% compliance
2022	5.8	7 lung pathology reports from 2021	70% compliance
2022	5.7	7 rectal pathology reports from 2021-2022	80% compliance
2023	5.8	7 lung pathology reports from 2021-2022	80% compliance
2024	5.7	7 rectal pathology reports from 2021-2023	80% compliance
2024	5.8	7 lung pathology reports from 2021-2023	80% compliance
2025	5.7	7 rectal pathology reports from 2022-2024	80% compliance
2025	5.8	7 lung pathology reports from 2022-2024	80% compliance





LINDA'S TIPS AND TRICKS

It does NOT count if you document that you LOOKED but didn't FIND


- Per Tim Mullett CAN count nodes evaluated on EBUS or MED must get it into the path report
 - TALK TO YOUR PATHOLOGISTS



How Can Programs Optimize Compliance?







Ensure institution is utilizing standardized CAP reports for all lung cancer procedures

Document performance of lymph node sampling during pulmonary resection & label stations clearly in operative note

Encourage communication amongst surgeons, pathologists, & registrars





Pre-labeled Specimen Collection Kits and Checklists Improve Communication



Overall performance of mediastinal lymph node examination Median number of MLN examined:







Concordance in surgeons' and pathologists' reporting









Osarogiagbon et al, 2012 Osarogiagbon et al, 2015





Standardized Collection Kits Improve Compliance With Pulmonary Nodal Staging









Summary

Standard 5.8: Pulmonary Resection

Operation

For any primary pulmonary resection performed with curative intent

(including non-anatomic parenchymal-sparing resections)

Resect nodal stations from:




Mediastinum (Stations 2-9) ≥3 distinct stations

Hilum (Stations 10-14) ≥1 station

Pathology Documentation

Synoptic report documents lymph nodes from:



with names and/or numbers of stations

When?

2021: **Implementation**

2022 site visits:

70% Compliance







References

- Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141(3):662-670.
- 2. De Leyn P, Dooms C, Kuzdzal J et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non small- cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5): 787-98.
- 3. National Comprehensive Cancer Network. NCCN clinical practice guidelines: Non-small cell lung cancer. Version 6.2019. August 12, 2019.
- 4. Nelson H, Hunt KK, Veeramachaneni N, et al. Operative Standards for Cancer Surgery, Volume I. Chicago, IL: Wolters Kluwer; 2015.
- 5. Osarogiagbon RU, Miller LE, Ramirez RA, et al. Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer. J Thorac Oncol. 2012 Aug;7(8):1276-82.
- 6. Osarogiagbon RU, Ray MA, Faris NR, et al. Prognostic value of National Comprehensive Care Network Lung cancer resection quality criteria. Ann Thorac Surg. 2017;103: 1557-65.
- 7. Osarogiagbon RU, Sareen S, Eke R et al. Audit of lymphadenectomy in lung cancer resections using a specimen collection kit and checklist. Ann Thorac Surg. 2015;99(2): 421-427.
- 8. Osarogiagbon RU, Yu X. Nonexamination of lymph nodes and survival after resection of non-small cell lung cancer. Ann Thorac Surg. 2013;96:1178-89.





Can You Meet the 2020 CoC Surgical Standards?



Standard 5.8 - Pulmonary Resection

Synoptic operative report

- NOT YET REQUIRED
- But now is a good time to start

Can You Meet the 2020 CoC Surgical Standards?



Lung Cancer Critical Elements of Synoptic



Preresection Staging
None
EBUS
EUS
Cervical mediastinoscopy
VATS/thoracotomy
Chamberlain

Preresection Nodal Staging (with Diagnostic Lymphoid Tissue)				
	N/A			
	Right nodal stations	Left nodal stations		
	2	2		
	4	4		
	7	5		
	8	6		
	9	7		
	10	8		
	Other N1	9		
		10		
		Other N1		

Nodal Evaluation at Time of Resection

Systematic sampling

Nodal Stations Examined at Time of Resection					
Model Stations Examined at Time of Resection					
	N/	A			
	Right nodal stations	Left nodal stations			
	2	2			
	4 7	4 5			
	8 9	6			
	9 10	7			
	Other N1	8 9			
		10			
		Other N1			
Method of Lung	g Resection				
VATS	Thorace	Thoracotomy			
Extent of Lung Resection					
Segmentectomy	Lobectomy	Pneumonectomy	Wedge resection		
	Component of non-anatomic resection as part of anatomic resection	yes no			



Nodal dissection

"People never improve unless they look to some standard or example higher or better than themselves." Tyron Edwards, American theologian 1809-1894

Useful Resources

https://www.facs.org/-/media/files/quality-programs/cancer/cssp/58 visual abstract.ashx

https://www.youtube.com/watch?v=tT2LkQNppX0

https://surgonctoday.libsyn.com/commission-on-cancer-standard-58-best-practices-to-meet-to-standard-for-nodal-assessment-during-a-curative-operation-for-lung-cancer

https://www.facs.org/-/media/files/qualityprograms/cancer/cssp/webinar standard 5 8 pulmonary resection.ashx

https://www.facs.org/-/media/files/quality-programs/cancer/cssp/best_practices_57_58_webinar.ashx 2022 Site Visit Preparation for CoC Standards 5.7 & 5.8 (facs.org)

